The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy

Major Depressive Disorder Clinical Trial

Official title:

The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02669082
• Other study ID #: Ramelteon-4002
• Secondary ID: JapicCTI-163143U
• Status: Completed
• Phase: Phase 4
• Start date: May 9, 2017
• Est. completion date: January 31, 2018

Study information

• Verified date: May 2019
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate exploratorily the effect of ramelteon 8 mg once daily for 8 weeks in the treatment of insomnia patients with depression by using actigraphy.

Description:

The drug being tested in this study is called ramelteon. Ramelteon is being tested to treat people who have insomnia with depression. This study will look at sleep activity of participants who take ramelteon.

The study will enroll approximately 30 patients. Participants will be administered:

• Ramelteon 8 mg

Participants will be asked to take 1 tablet orally at bedtime. This multi-center study will be conducted in Japan. The overall period to participate in this study is 9 weeks (Run-in period for 1 week and treatment period for 8 weeks). Participants will make multiple visits to clinic including the final visit 8 weeks after the start of treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: January 31, 2018
• Est. primary completion date: January 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 64 Years

Eligibility

Inclusion Criteria:

1. Has difficulty in initiating sleep at least 3 days per week for at least 4 weeks at the time of informed consent.

2. Has Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5)-defined depression.

3. Man or woman between 20 and 64 years of age, inclusive, at the time of informed consent.

4. Outpatient.

5. Meets either of the following criteria based on the 17-item Hamilton Rating Scale for Depression (HAM-D17) both at the start of the run-in period and the start of the study treatment period: has a score of 2 for "6: Insomnia Early", or has a score of 1 for "6: Insomnia Early" AND a score of at least 3 in total for "7: Insomnia Middle" and "8: Insomnia Late".

6. Has a total HAM-D17 score of 16 or under both at the start of the run-in period and the start of the study treatment period.

7. Under treatment of the same antidepressant agents on a stable dose for at least 4 weeks before the start of the run-in period.

8. Goes to bed routinely in a daily life (time for bed between 21.00 p.m. and 1.00 a.m. at least 4 days per week).

9. Actigraphy shows at least 3 days with sleep latency 30 minutes or longer AND total nocturnal sleep time 6.5 hours or shorter on the same day during the run-in period.

10. In the opinion of the principal investigator or investigator, is capable of understanding the contents of the study and complying with study requirements.

11. Is capable of signing and dating the informed consent form in person before any study procedures.

Exclusion Criteria:

1. Has a history of hypersensitivity to ramelteon and melatonin.

2. Has severe liver disorder.

3. Took ramelteon within 4 weeks before the informed consent.

4. Using any insomnia medications (including investigational drugs and unapproved drugs) for 2 weeks before the treatment period.

5. Shift worker or night worker.

6. Has complications of psychiatric or neurological diseases that affect sleep state other than depression.

7. Has a HAM-D17 score of at least 1 for"11: Suicide" at the start of the run-in period or the start of the study treatment period, or any suicide attempts within 24 weeks before or during the run-in period.

8. Pregnant woman, nursing mother, or woman who plans to become pregnant or donate eggs before the informed consent, during the study period or within 4 weeks after the end of the study.

9. Is participating in any other investigational or post-marketing clinical trial/study.

10. For other reason, judged not appropriate for participation in this study by the principal investigator or investigator.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Disease
• Insomnia
• Major Depressive Disorder
• Sleep Initiation and Maintenance Disorders

Intervention

Drug:
• Ramelteon
Ramelteon tablets

Locations

Country	Name	City	State
Japan	You Ariyoshi Sleep Clinic	Kitakyushu	Fukuoka
Japan	Senzoku Psychosomatic Clinic	Meguro	Tokyo
Japan	Ishikawa Mental Clinic	Sapporo	Hokkaido
Japan	Minami 1jo Mental Clinic	Sapporo	Hokkaido
Japan	Sangenjaya Neurology and Psychosomatic Clinic	Setagaya	Tokyo
Japan	Himorogi Kokorono Clinic	Shinjuku	Tokyo
Japan	Seiwa Hospital	Shinjuku	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Actigraphy-Measured Sleep Latency at the End of the Treatment Period	Sleep latency was defined as time period measured from "lights out," or bedtime, to the beginning of sleep. Sleep latency was assessed by actigraphy, a non-intrusive tool that measures an individual's movement during sleep. Mean value from the past 7 days was evaluated. A negative change from Baseline indicates improvement.	Baseline and the end of the Treatment Period (up to Week 8)
Secondary	Change From Baseline in Diary-Measured Sleep Latency at the End of the Treatment Period	Sleep latency was defined as time period measured from "lights out," or bedtime, to the beginning of sleep. Sleep latency was recorded by the participant in a diary. Mean value from the past 7 days at each timepoint was evaluated. A negative change from Baseline indicates improvement.	Baseline and the end of the Treatment Period (up to Week 8)
Secondary	Change From Baseline in Actigraphy-Measured Total Nocturnal Sleep Time at the End of the Treatment Period	Total nocturnal sleep time was assessed by actigraphy, a non-intrusive tool that measures an individual's movement during sleep. Total nocturnal sleep time by actigraphy was total time in bed from which sleep latency, nocturnal wake time, and the time from waking up to leaving the bed were subtracted. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates improvement.	Baseline and the end of the Treatment Period (up to Week 8)
Secondary	Change From Baseline in Actigraphy-Measured Nocturnal Wake Time at the End of the Treatment Period	Nocturnal wake time is the total time that is scored between nocturnal sleep onset and final wake-up. Nocturnal wake time was assessed by actigraphy, a non-intrusive tool that measures an individual's movement during sleep. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates a worsening.	Baseline and the end of the Treatment Period (up to Week 8)
Secondary	Change From Baseline in Actigraphy-Measured Number of Nocturnal Awakenings at the End of the Treatment Period	The number of nocturnal awakenings were assessed by actigraphy which is a non-intrusive tool that measures an individual's movement during sleep. Mean value from the past 7 days at each time point was evaluated. A positive change from Baseline indicates a worsening.	Baseline and the end of the Treatment Period (up to Week 8)
Secondary	Change From Baseline in Actigraphy-Measured Sleep Efficiency at the End of the Treatment Period	Sleep efficiency was defined as percentage of sleep in the period potentially filled by sleep-ratio of total sleep time to time in bed calculated as [(Total sleep time/total time in bed) * 100]. Sleep efficiency was assessed by actigraphy, a non-intrusive tool that measures an individual's movement during sleep. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates improvement.	Baseline and the end of the Treatment Period (up to Week 8)
Secondary	Change From Baseline in Diary-Measured Total Nocturnal Sleep Time at the End of the Treatment Period	Total nocturnal sleep time by diary was calculated as total time in bed (awaking hour - bedtime hour) from which sleep latency was subtracted. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates improvement.	Baseline and the end of the Treatment Period (up to Week 8)
Secondary	Change From Baseline in Diary-Measured Number of Nocturnal Awakenings at the End of the Treatment Period	The number of nocturnal awakenings were recorded by the participant in a diary. Mean value from the past 7 days at each timepoint was evaluated. A negative change from Baseline indicates improvement.	Baseline and the end of the Treatment Period (up to Week 8)
Secondary	Change From Baseline in Actigraphy-Measured Daytime Activity Level, as Evaluated by the Number of Footsteps, at the End of the Treatment Period	Daytime activity level, as evaluated by the number of footsteps, were assessed by actigraphy, a non-intrusive tool that measures an individual's movement. Mean value from the past 7 days at each timepoint was evaluated. A positive change from Baseline indicates improvement.	Baseline and the end of the Treatment Period (up to Week 8)